Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 5/20 | 0.59 |
| ▸ | MAOB | P27338 | 2/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.59 |
| ▸ | CALML3 | P27482 | 1/20 | 0.59 |
| ▸ | SDHA | P31040 | 1/20 | 0.59 |
| ▸ | F10 | P00742 | 7/20 | 0.57 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8590209 | 1.00 | MAOA (0.59) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL9550282 | 0.96 | MAOA (0.56) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL13298924 | 0.90 | MAOA (0.61) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL5764261 | 0.88 | F10 (0.54) | F10 | |
| SCHEMBL16703808 | 0.88 | MAOA (0.60) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL9550292 | 0.88 | MAOA (0.60) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL15367964 | 0.88 | MAOA (0.60) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL9823761 | 0.87 | MAOA (0.65) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL18770274 | 0.87 | MAOA (0.59) | MAOAMAOBLMNAPTGS1CALML3 | |
| Dup-721 SCHEMBL4402113 | 0.87 | ABCB11 (0.59) | MAOAMAOBLMNAPTGS1CALML3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1816548-B | cyclopropyl substituted oxazolidinone antibiotics and derivatives thereof | MERCK & CO INC | 2011-01-12 | — | — | CN | disclosed |
| EP-1646629-B1 | CYCLOPROPYL GROUP SUBSTITUTED OXAZOLIDINONE ANTIBIOTICS AND DERIVATIVES THEREOF | MERCK SHARP & DOHME (US) | 2010-06-23 | — | — | EP | disclosed |
| US-20100137243-A1 | Oxazolidinone And/Or Isoxazoline As Antibacterial Agents | ASTRAZENECA AB (SE) | 2010-06-03 | — | — | US | disclosed |
| US-7582659-B2 | Cyclopropyl group substituted oxazolidinone antibiotics and derivatives thereof | MERCK & CO., INC. (US) | 2009-09-01 | — | — | US | disclosed |
| US-7462633-B2 | Cyclopropyl group substituted oxazolidinone antibiotics and derivatives thereof | MERCK & CO., INC. (US) | 2008-12-09 | — | — | US | disclosed |
| US-7396847-B2 | Oxazolidinone and/or isoxazoline as antibacterial agents | ASTRAZENECA AB (SE) | 2008-07-08 | — | — | US | disclosed |
| US-20070203187-A1 | Cyclopropyl group substituted oxazolidinone antibiotics and derivatives thereof | MERCK & CO., INC. (US) | 2007-08-30 | — | — | US | disclosed |
| US-20070185132-A1 | Cyclopropyl group substituted oxazolidinone antibiotics and derivatives thereo | MERCK & CO., INC. | 2007-08-09 | — | — | US | disclosed |
| US-7094900-B2 | N-Aryl-2-oxazolidinones and their derivatives | PHARMACIA & UPJOHN COMPANY LLC (US) | 2006-08-22 | — | — | US | disclosed |
| CN-1816548-A | cyclopropyl substituted oxazolidinone antibiotics and derivatives thereof | MERCK & CO INC (US) | 2006-08-09 | — | — | CN | disclosed |
| US-20050107435-A1 | Oxazolidinone and/or isoxazoline as antibacterial agents | ASTRAZENECA AB (SE) | 2005-05-19 | — | — | US | disclosed |
| US-20050038092-A1 | Cyclopropyl group substituted oxazolidinone antibiotics and derivatives thereof | MERCK SHARP & DOHME CORP. | 2005-02-17 | — | — | US | disclosed |
| WO-2005005420-A1 | CYCLOPROPYL GROUP SUBSTITUTED OYAZOLIDINONE ANTIBIOTICS AND DERIVATIVES THEREOF | MERCK & CO., INC. (US) | 2005-01-20 | — | — | WO | disclosed |
| WO-2005005398-A2 | CYCLOPROPYL GROUP SUBSTITUTED OXAZOLIDINONE ANTIBIOTICS AND DERIVATIVES THEREOF | MERCK & CO., INC. (US) | 2005-01-20 | — | — | WO | disclosed |
| EP-1427711-A1 | OXAZOLIDINONE AND/OR ISOXAZOLINE DERIVATIVES AS ANTIBACTERIAL AGENTS | AstraZeneca AB (SE) | 2004-06-16 | — | — | EP | disclosed |
| US-20040072873-A1 | N-Aryl-2-oxazolidinones and their derivatives | GADWOOD ROBERT C (US) | 2004-04-15 | — | — | US | disclosed |
| EP-1385834-A1 | BICYCLO[3,1,0]HEXANE CONTAINING OXAZOLIDINONE ANTIBIOTIC AND DERIVATIVES THEREOF | Merck & Co., Inc. (US) | 2004-02-04 | — | — | EP | disclosed |
| US-20030125367-A1 | Bicyclo[3,1,0]hexane containing oxazolidinone antibioytics and derivatives thereof | KYORIN PHARMACEUTICAL CO., LTD. | 2003-07-03 | — | — | US | disclosed |
| WO-2003027083-A1 | BICYCLO[3,1,0]HEXANE CONTAINING OXAZOLIDINONE ANTIBIOTIC AND DERIVATIVES THEREOF | MERCK & CO., INC. (US) | 2003-04-03 | — | — | WO | disclosed |
| WO-2003022824-A1 | OXAZOLIDINONE AND/OR ISOXAZOLINE AS ANTIBACTERIAL AGENTS | ASTRAZENECA AB (SE) | 2003-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203187-A1 | Cyclopropyl group substituted oxazolidinone antibiotics and derivatives thereof | OXA1L, ALAD, COASY | MAOA 2977/4885MAOB 1835/4885LMNA 4147/4885 |
| US-20100137243-A1 | Oxazolidinone And/Or Isoxazoline As Antibacterial Agents | CYP8B1, HRH2, CYP2W1 | MAOA 482/4885MAOB 192/4885LMNA 2170/4885 |
| US-20050107435-A1 | Oxazolidinone and/or isoxazoline as antibacterial agents | CYP8B1, CYP2W1, HRH2 | MAOA 800/4885MAOB 328/4885LMNA 2177/4885 |
| US-20070185132-A1 | Cyclopropyl group substituted oxazolidinone antibiotics and derivatives thereo | IL17A, COASY, OXA1L | MAOA 2435/4885MAOB 1387/4885LMNA 4333/4885 |
| US-20050038092-A1 | Cyclopropyl group substituted oxazolidinone antibiotics and derivatives thereof | OXA1L, ALAD, COASY | MAOA 2977/4885MAOB 1835/4885LMNA 4147/4885 |
| US-20030125367-A1 | Bicyclo[3,1,0]hexane containing oxazolidinone antibioytics and derivatives thereof | NR4A1, NR0B1, NR1D1 | MAOA 3466/4885MAOB 3207/4885LMNA 3824/4885 |
| US-20040072873-A1 | N-Aryl-2-oxazolidinones and their derivatives | OXA1L, NDUFS7, NDUFS6 | MAOA 854/4885MAOB 678/4885LMNA 3740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.